Table 2 Factors predictive of virological relapse after entecavir or TAF cessation for all patients
Variables | Comparison | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | ||
Age (years) | Increase per one year | 0.991 (0.972–1.011) | 0.383 | ||
Gender | Male vs. female | 0.9523 (0.603–1.414) | 0.713 | ||
Use of Rituximab | Yes vs. no | 2.123 (1.201–3.752) | 0.010 | ||
Use of steroid | Yes vs. no | 1.964 (1.070–3.606) | 0.029 | ||
Use of anthracycline | Yes vs. no | 1.346 (0.885–2.047) | 0.164 | ||
Hematologic malignancy | Yes vs. no | 2.326 (1.372–3.943) | 0.002 | 2.034 (1.178–2.513) | 0.011 |
Distant metastasis | Yes vs. no | 1.032 (0.594–1.795) | 0.910 | ||
NA therapy | TAF vs. entecavir | 1.231 (0.994–1.525) | 0.056 | 1.386 (1.109–1.732) | 0.004 |
AST (U/L) | Increase per one U/L | 1.003 (1.001–1.006) | 0.019 | ||
ALT (U/L) | Increase per one U/L | 1.002 (1.001–1.004) | 0.008 | ||
Total bilirubin | Increase per one mg/dL | 1.251 (0.749–2.087) | 0.392 | ||
Platelet × 103/μL | Increase per 103/μL | 0.998 (0.996–1.001) | 0.146 | ||
FIB-4 | Increase per ratio | 1.192 (0.989–1.436) | 0.065 | ||
Viremia groups* |  < 0.001 |  < 0.001 | |||
Low-viremia group | Reference | Reference | |||
Moderate-viremia group | 1.670 (0.802–3.479) | 0.171 | 1.671 (0.802–3.482) | 0.171 | |
High-viremia group | 6.983 (3.553–13.724) |  < 0.001 | 6.975 (3.533–13.769) |  < 0.001 | |
HBsAg level at EOT (IU/mL)** | Increase per one log IU/mL | 2.285 (1.825–2.860) |  < 0.001 | ||
Treatment duration | Increase per one week | 1.001 (0.992–1.011) | 0.759 | ||
Consolidation duration | Increase per one week | 1.009 (0.991–1.027) | 0.352 | ||